Stock Events

Stock Events

Replimune Group 

$7.65
36
+$0.45+6.25% Tuesday 20:00

Statistics

Day High
7.88
Day Low
7.25
52W High
13.24
52W Low
2.68
Volume
2,129,964
Avg. Volume
1,431,015
Mkt Cap
631.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.95
-0.86
-0.77
-0.68
Expected EPS
-0.707202
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-494.59MNet Income

Analyst Ratings

$13.33Average Price Target
The highest estimate is 19.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REPL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. has a broad portfolio in oncology, including immuno-oncology treatments that compete with Replimune's cancer therapies.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers Keytruda, a leading immunotherapy drug, which competes in the broader cancer treatment market against Replimune's products.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a strong lineup of cancer drugs, including immunotherapies that rival Replimune's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is involved in the development of cancer therapies, including cell therapies, which can be seen as competitive to Replimune's viral-based treatments.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc., while primarily known for vaccines, is exploring cancer vaccine candidates that could potentially compete with Replimune's viral immunotherapies.
Iovance Biotherapeutics
IOVA
Mkt Cap712.85M
Iovance Biotherapeutics, Inc. specializes in tumor-infiltrating lymphocyte (TIL) therapies for cancer, offering a different but competitive approach to Replimune's methods.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diverse oncology portfolio, including investments in immunotherapies that compete with the innovative cancer treatments developed by Replimune.

About

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Show more...
CEO
Dr. Sushil Patel Ph.D.
Employees
479
Country
US
ISIN
US76029N1063

Listings

F
DE
7R8.F
XNAS
US
REPL
BOATS
BOATS
REPL.BOATS

0 Comments

Share your thoughts

FAQ

What is Replimune Group stock price today?▼
The current price of REPL is $7.65 USD — it has increased by +6.25% in the past 24 hours. Watch Replimune Group stock price performance more closely on the chart.
What is Replimune Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Replimune Group stocks are traded under the ticker REPL.
Is Replimune Group stock price growing?▼
REPL stock has risen by +1.19% compared to the previous week, the month change is a +0% rise, over the last year Replimune Group has showed a -8.93% decrease.
What is Replimune Group market cap?▼
Today Replimune Group has the market capitalization of 631.68M
When is the next Replimune Group earnings date?▼
Replimune Group is going to release the next earnings report on May 14, 2026.
What were Replimune Group earnings last quarter?▼
REPL earnings for the last quarter are -0.77 USD per share, whereas the estimation was -0.76 USD resulting in a -0.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Replimune Group revenue for the last year?▼
Replimune Group revenue for the last year amounts to 0 USD.
What is Replimune Group net income for the last year?▼
REPL net income for the last year is -494.59M USD.
How many employees does Replimune Group have?▼
As of April 01, 2026, the company has 479 employees.
In which sector is Replimune Group located?▼
Replimune Group operates in the Health Care sector.
When did Replimune Group complete a stock split?▼
The last stock split for Replimune Group was on December 01, 2010 with a ratio of 15:1.
Where is Replimune Group headquartered?▼
Replimune Group is headquartered in Woburn, US.